Clinical Trial Update: Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing datopotamab deruxtecan (DS-1062a) to docetaxel in previously treated advanced or metastatic non-small cell lung cancer has posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• DS-1062a (datopotamab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-07-23